ADVERTISEMENT

Sun Pharma Q4 Review: Strong Domestic Growth Offset By Weakness In US Generics; Systematix Maintains 'Buy'

Systematix tweaks its estimates to account for the updated tax guidance and contribution from new launches on the specialty front.

<div class="paragraphs"><p>&nbsp; (Photo Source: Company website)</p></div>
  (Photo Source: Company website)
Sun Pharma has also guided for an investment of $100 million in new launches. During the year, besides new launches, Sun Pharma will also unveil important clinical data on its new chemical entity pipeline (Vibozilimod, Ilumya in psoriatic arthritis) and the clinical data should be important as it would shape sentiment around medium to long term growth.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit